Abstract
Numerous cellular pathways have a significant impact in the growth and metastatic potential of tumors. Essential element of such pathways is the epidermal growth factor receptor (EGFR), a member of the HER family of receptor tyrosine kinases. One of the most important issues in cancer, which attracted the attention of clinical oncologists, is the potential use of targeted therapies. EGFR signaling pathway is implicated in the control of cell survival, proliferation, metastasis and angiogenesis. EGFR is, therefore, an appealing target for molecular-targeted cancer therapy as it is expressed in a variety of solid tumors (colorectal, breast, head and neck, etc.). Receptor antagonists that target EGFR have already been of high interest for a number of years. Multiple therapeutic strategies have been developed to target EGFR, including monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), ligand-toxin conjugates, and antisense oligonucleotides. In particular, mAbs block ligand from binding to the extracellular domain of the receptor. Two mAbs that block EGFR (erbB1), cetuximab and panitumumab, have been approved by FDA. Cetuximab is a chimeric IgG1 anti-EGFR monoclonal antibody, whereas panitumumab is a fully human IgG2 anti-EGFR monoclonal antibody. This review highlights the cellular effects of EGFR blockade by mAbs and their relationship to therapeutic efficacy and biological significance.
Keywords: Epidermal growth factor receptor, solid tumors, colorectal cancer, anti-EGFR therapy, monoclonal antibodies, cetuximab, panitumumab
Current Medicinal Chemistry
Title: Targeting Epidermal Growth Factor Receptor in Solid Tumors: Critical Evaluation of the Biological Importance of Therapeutic Monoclonal Antibodies
Volume: 16 Issue: 29
Author(s): Ch. Gialeli, D. Kletsas, D. Mavroudis, H. P. Kalofonos, G. N. Tzanakakis and N. K. Karamanos
Affiliation:
Keywords: Epidermal growth factor receptor, solid tumors, colorectal cancer, anti-EGFR therapy, monoclonal antibodies, cetuximab, panitumumab
Abstract: Numerous cellular pathways have a significant impact in the growth and metastatic potential of tumors. Essential element of such pathways is the epidermal growth factor receptor (EGFR), a member of the HER family of receptor tyrosine kinases. One of the most important issues in cancer, which attracted the attention of clinical oncologists, is the potential use of targeted therapies. EGFR signaling pathway is implicated in the control of cell survival, proliferation, metastasis and angiogenesis. EGFR is, therefore, an appealing target for molecular-targeted cancer therapy as it is expressed in a variety of solid tumors (colorectal, breast, head and neck, etc.). Receptor antagonists that target EGFR have already been of high interest for a number of years. Multiple therapeutic strategies have been developed to target EGFR, including monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), ligand-toxin conjugates, and antisense oligonucleotides. In particular, mAbs block ligand from binding to the extracellular domain of the receptor. Two mAbs that block EGFR (erbB1), cetuximab and panitumumab, have been approved by FDA. Cetuximab is a chimeric IgG1 anti-EGFR monoclonal antibody, whereas panitumumab is a fully human IgG2 anti-EGFR monoclonal antibody. This review highlights the cellular effects of EGFR blockade by mAbs and their relationship to therapeutic efficacy and biological significance.
Export Options
About this article
Cite this article as:
Gialeli Ch., Kletsas D., Mavroudis D., Kalofonos P. H., Tzanakakis N. G. and Karamanos K. N., Targeting Epidermal Growth Factor Receptor in Solid Tumors: Critical Evaluation of the Biological Importance of Therapeutic Monoclonal Antibodies, Current Medicinal Chemistry 2009; 16 (29) . https://dx.doi.org/10.2174/092986709789177984
DOI https://dx.doi.org/10.2174/092986709789177984 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The TWEAK-Fn14 System: Breaking the Silence of Cytokine-Induced Skeletal Muscle Wasting
Current Molecular Medicine Editorial (Thematic Issue: Self-Assembled Organic Nanostructures in Medicinal Chemistry: Advances and Applications)
Current Topics in Medicinal Chemistry Advances in α(v)β(3) Integrin-Targeting Cancer Therapy and Imaging with Radiolabeled RGD Peptides
Current Radiopharmaceuticals Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Inhibition of HIV-1 Replication by RNA-Based Strategies
Current HIV Research NRG1-ErbB Lost in Translation: A New Paradigm for Lung Cancer?
Current Medicinal Chemistry Chemical Composition and Biological Activities of <i>Croton delpyi, Croton decalvatus</i> and <i>Croton caudatus</i>
The Natural Products Journal Remyelination in Multiple Sclerosis: The Therapeutic Potential of Neural and Mesenchymal Stem/Progenitor Cells
Current Signal Transduction Therapy Discussion on the Structural Modification and Anti-tumor Activity of Flavonoids
Current Topics in Medicinal Chemistry Mutant Cell Surface Receptors as Targets for Individualized Cancer Diagnosis and Therapy
Current Cancer Drug Targets Editorial [Hot Topic: Nitric Oxide: Implications for the Etiology & Treatment of Central Nervous System Disorders (Guest Editor: Giuseppe Di Giovanni)]
CNS & Neurological Disorders - Drug Targets Recent Advances in Delivery Through the Blood-Brain Barrier
Current Topics in Medicinal Chemistry Chemical Modifications of Ketoprofen (NSAID) in Search of Better Lead Compounds: A Review of Literature From 2004-2016
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Benzofuran Small Molecules as Potential Inhibitors of Human Protein Kinases. A Review
Current Pharmaceutical Design Resveratrol in Cancer: Cellular and Mitochondrial Consequences of Proton Transport Inhibition
Current Pharmaceutical Design Medicinal Plants for Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research Marine Actinomycetes-derived Natural Products
Current Topics in Medicinal Chemistry Different Treatment Strategies for Pediatric Brain Tumors
Current Pediatric Reviews Combinatorial Inhibition of mTORC2 and Hsp90 Leads to a Distinctly Effective Therapeutic Strategy in Malignant Pheochromocytoma
Current Cancer Drug Targets